...INCY completed its previously announced acquisition of Maxia, a developer of small molecule protein phosphatase inhibitors...
...in clinical milestones (see BioCentury, Nov. 18, 2002). Incyte Genomics Inc. (INCY), Palo Alto, Calif. Maxia Pharmaceuticals Inc....

...INCY announced that it will acquire Maxia, a developer of small molecule protein phosphatase inhibitors, for...
...said Maxia's programs in cancer and inflammation complement its small molecule and protein therapeutic programs. Maxia's...
...II testing for cervical dysplasia, a precancerous condition. Incyte Genomics Inc. (INCY), Palo Alto, Calif. Maxia Pharmaceuticals Inc....

...was reflected in moves last week by two of these companies. Incyte Genomics Inc. purchased Maxia Pharmaceuticals Inc....
...of Maxia (San Diego, Calif.). Maxia develops small molecule protein phosphatase inhibitors, and INCY said Maxia's...
...the next year, INCY said it plans to hire 80-100 scientists, including those from the Maxia...

...in stock for its stem cell technologies. Incyte Genomics Inc. (INCY, Palo Alto, Calif.) acquired Maxia Pharmaceuticals Inc....

...add 80-100 next year to support drug discovery; current headcount does not account for planned Maxia...

...next year to support its drug discovery programs. Separately, INCY announced that it will acquire Maxia...
...said Maxia's programs in cancer and inflammation complement its small molecule and protein therapeutic programs. Maxia's...

...Business: Cancer, Cardiovascular Hired: Wood Erwin as VP of finance and CFO, formerly CFO at Maxia Pharmaceuticals Inc. WIR...

...therapy, Transplant Hired: Richard Piazza as CEO and a director, formerly president and CEO at Maxia Pharmaceuticals Inc. WIR...

...in 1999 to join nutraceutical play PharmaPrint as president and CEO, and in 2001 joined Maxia...

...$12.2M BioNumerik $12.0M Withdrew IPO on 11/01 Xanthon $12.0M Pharmadigm $12.0M Metabolex $10.8M GeneMachines $10.7M Maxia...